New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 30, 2014
08:04 EDTARNAArena Pharmaceuticals and Eisai announce results of Lorcaserin Phase 2 trial
Arena Pharmaceuticals and Eisai announced that an article based on post-hoc analyses from the three pivotal Phase 3 trials of lorcaserin was recently published in the official peer reviewed journal of The Obesity Society. The objective of these analyses was to identify whether there is an early treatment milestone that can predict greater than or equal to 5% weight loss at one year in patients treated with lorcaserin. Belviq is a serotonin 2C receptor agonist approved in the U.S. as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in obese or overweight adults with at least one weight-related medical condition, such as high blood pressure, high cholesterol, or type 2 diabetes.
News For ARNA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 29, 2015
08:22 EDTARNAArena Pharmaceuticals begins Phase 2 trial of candidate for autoimmune diseases
Subscribe for More Information
July 21, 2015
15:42 EDTARNAArena Pharmaceuticals receives USPTO patent
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use